MedTrace Logo

RCT of Pulp Capping Over Carious Exposure in Adults

NCT01224925 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2019-03-18

Study results available
· View outcomes & findings →

Summary

This multicentre study was a randomized, controlled, parallel, patient-blinded, two-arm superiority trial with a 1:1 allocation ratio that followed the CONSORT guidelines.The aim of this study was to investigate whether MTA is more effective than a conventional calcium hydroxide liner (Dycal®) as a direct pulp capping material in mature molar teeth with a carious pulpal exposure.

Conditions

  • Carious Exposure
  • Human Permanent First and Second Molars
  • Mature Teeth
  • Proximal Caries
  • Healthy Pulp
  • Reversible Pulpitis

Interventions

PROCEDURE

Direct pulp capping with Dycal

Capping over carious exposure with Dycal. Dycal: covered with Fuji IX. After one week, part of the temporary filling was left under the permanent filling

PROCEDURE

Direct pulp capping

WMTA capping over exposed pulp, wet pellet, Fuji IX. After one week, the entire temporary filling was removed,the cavity was permanently restored with a composite resin material used at the study clinic.

Sponsors & Collaborators

  • Norwegian Public dental health service

    collaborator UNKNOWN

  • University of Tromso

    lead OTHER

Principal Investigators

  • Rita Kundzina, DDS, PhD · University of Tromso,Faculty of Health Sciences, Institute of Clinical Dentistry

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-18
Primary Completion
2015-12-10
Completion
2015-12-10

Countries

  • Lithuania
  • Norway

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01224925 on ClinicalTrials.gov